COVID-19 Research Paper Volume 13, Issue 13 pp 16904—16921

Prognostic and immunological value of ATP6AP1 in breast cancer: implications for SARS-CoV-2

Changes in ATP6AP1 levels after SARS-CoV-2 infections. (A) Comparison of ATP6AP1 levels between the mock (n = 3) and SARS-CoV-2-infected groups (n = 6) of iAT2 cells from the GSE153277 dataset. Triplicate results are shown for iAT2 cells cultured at the air-liquid interface with a mock virus (mock, n = 3), with SARS-CoV-2 one day post-infection (1 dpi, n = 3), and with SARS-CoV-2 four days post-infection (4 dpi, n = 3). (B) ATP6AP1 levels in the SARS-CoV-2-infected group (n = 6) and the mock group (n = 3) of hPSC-LOs from the GSE155241 dataset. CPM: counts per million. RPKM: reads per kilobase million.

Figure 7. Changes in ATP6AP1 levels after SARS-CoV-2 infections. (A) Comparison of ATP6AP1 levels between the mock (n = 3) and SARS-CoV-2-infected groups (n = 6) of iAT2 cells from the GSE153277 dataset. Triplicate results are shown for iAT2 cells cultured at the air-liquid interface with a mock virus (mock, n = 3), with SARS-CoV-2 one day post-infection (1 dpi, n = 3), and with SARS-CoV-2 four days post-infection (4 dpi, n = 3). (B) ATP6AP1 levels in the SARS-CoV-2-infected group (n = 6) and the mock group (n = 3) of hPSC-LOs from the GSE155241 dataset. CPM: counts per million. RPKM: reads per kilobase million.